Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer.

The company is the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

The company?s first ADC product brentuximab vedotin (Adcetris?)?received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2011 and approval with conditions from Health Canada in February 2013 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, an aggressive type of T-cell non-Hodgkin lymphoma. ?Additionally, the European Commission granted?Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company?conditional marketing authorization in October 2012.?Millennium has exclusive rights to commercialize the product candidate for Seattle Genetics outside the United States and Canada.

21823 – 30th Drive S.E. – Mailing address
21717 – 30th Drive S.E. – Building 3/Reception
Bothell, WA 98021
U.S.A.

Web: Seattle Genetics, Inc

Advertisement #3
Advertisement #5